SLP - Simulation Plus: Fantastic Total Return With 50% Increase In Price In Last Three Months
Simulation Plus (SLP) is a choice for the speculative growth investor looking for the latest technology in drug development. Simulation Plus is a provider of simulation and modeling software for pharmaceutical product development in the United States and foreign countries. What interested me in this company was their product and, most of all, the high inside ownership of 30%.
Simulation Plus is being reviewed using The Good Business Portfolio guidelines, but some of my guidelines are not germane for a small cap company like SLP. The company has the cash it uses to